Insider Transactions in Q3 2024 at Ligand Pharmaceuticals Inc (LGND)
Insider Transaction List (Q3 2024)
Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Aug 28
2024
|
Octavio Espinoza Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
753
+1.52%
|
$47,439
$63.63 P/Share
|
Aug 28
2024
|
Andrew Reardon CLO & Secretary |
SELL
Open market or private sale
|
Direct |
1,500
-6.24%
|
$159,000
$106.39 P/Share
|
Aug 28
2024
|
Andrew Reardon CLO & Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+5.87%
|
$78,000
$52.27 P/Share
|
Aug 26
2024
|
Matthew E Korenberg President & COO |
SELL
Open market or private sale
|
Direct |
11,389
-9.83%
|
$1,195,845
$105.67 P/Share
|
Aug 23
2024
|
Matthew E Korenberg President & COO |
SELL
Open market or private sale
|
Direct |
6,312
-4.8%
|
$656,448
$104.61 P/Share
|
Aug 22
2024
|
Matthew E Korenberg President & COO |
SELL
Open market or private sale
|
Direct |
1,157
-1.69%
|
$121,485
$105.54 P/Share
|
Aug 09
2024
|
Matthew E Korenberg President & COO |
SELL
Open market or private sale
|
Direct |
18,245
-21.07%
|
$1,788,010
$98.5 P/Share
|
Aug 08
2024
|
Todd C Davis Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
2,500
+1.99%
|
$242,500
$97.39 P/Share
|